BLUE: A Potential Cure For SCD May Not Be Far Fetched, Says Roth Capital
In a research report published Monday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on bluebird bio (NASDAQ:BLUE) and raised his price target to $120, which implies an upside of 31% from current levels.
Chattopadhyay said, “With a potential cure for ß-thalassemia within reach, attention has now gravitated towards the impending readout from Sickle Cell Disease (SCD). In the ß-thalassemia studies, patients achieving transfusion independence with high levels of ßA-T87Q-globin in peripheral blood. SCD is not a homogenous disease and patients with high fetal hemoglobin (HgF) and HbA-expression have a milder phenotype. Hence, increasing ßA-T87Q-globin could translate to reduction in disease burden and transform severe SCD into a milder phenotype.”
According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 3.3% and a 47.6% success rate. Chattopadhyay has a 94.4% average return when recommending BLUE, and is ranked #1231 out of 3426 analysts.